Beta-glucocerebrosidase (GBA) (GBA)

Beta-glucocerebrosidase (GBA) is a critical lysosomal enzyme responsible for the hydrolysis of glucocerebroside (glucosylceramide) into glucose and ceramide (UniProt P04062). A deficiency in GBA activity, typically caused by biallelic mutations in the GBA1 gene, leads to Gaucher disease, a lysosomal storage disorder where the lipid substrate accumulates within macrophages, forming Gaucher cells that infiltrate the spleen, liver, and bone marrow (NIH GARD). This accumulation results in clinical manifestations such as hepatosplenomegaly, cytopenias, and debilitating bone disease (Stirnemann et al., 2017). Furthermore, GBA1 mutations are recognized as the most significant genetic risk factor for Parkinson's disease and Lewy body dementia, likely due to the role of GBA in alpha-synuclein clearance (Sidransky & Lopez, 2012). Therapeutic strategies primarily involve enzyme replacement therapy (ERT) using recombinant forms like imiglucerase to restore metabolic function (FDA). Other approaches include substrate reduction therapy (SRT) to decrease glucocerebroside synthesis and pharmacological chaperones designed to stabilize the mutant enzyme and improve its lysosomal delivery (PubChem).

Other names

GlucosylceramidaseAcid beta-glucosidaseGBA1GlucocerebrosidaseAcid glucosidase

Enzyme replacement therapy (ERT) provides a recombinant version of the enzyme to hydrolyze accumulated glucocerebroside; substrate reduction therapy (SRT) inhibits the synthesis of the substrate; pharmacological chaperones stabilize the enzyme's structure to enhance its activity and trafficking.